Whitney Ijem

Q: How accurate are Whitney Ijem's stock ratings?

About 49% of Whitney's ratings were profitable over a one-year hold, with an average return of +1.0% per rating, measured by 13Foresight from historical prices.

Q: How is Whitney ranked?

Whitney Ijem is ranked #1848 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Canaccord Genuity

Wall Street Analyst

★★★☆☆

#1848

on 13Foresight · ranked by our own returns

49%

Success Rate

+0.9%

Average Return

31 of 63 calls profitable · -2.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 49% of Whitney Ijem's ratings turned a profit when each position was held for 1 year — averaging +0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

118 Buy 8 Hold 0 Sell

Whitney's Stock Coverage 32 ratings · 2026-09-02

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
BMRN BioMarin Pharmaceutical	Aug 31, 2026	BUY	Strong Buy +46.1% avg upside 52 analysts	$114.00 70.30% Upside	·	·
ALNY Alnylam Pharma	Aug 28, 2026	BUY	Strong Buy +27.8% avg upside 51 analysts	$429.00 60.42% Upside	+12.8%	·
ARCT Arcturus Therapeutics	Aug 20, 2026	BUY	Buy +85.8% avg upside 36 analysts	$20.00 19.42% Upside	+47.1%	·
RARE Ultragenyx Pharmaceutical	Aug 20, 2026	BUY	Strong Buy +160.2% avg upside 36 analysts	$83.00 212.83% Upside	+1.1%	·
NGNE Neurogene	Aug 12, 2026	BUY	Strong Buy +27.9% avg upside 23 analysts	$166.00 332.69% Upside	+2.4%	·
GUTS Fractyl Health, Inc.	Aug 12, 2026	BUY	Strong Buy +550.3% avg upside 7 analysts	$8.00 1032.08% Upside	+6.6%	·
BBIO BridgeBio Pharma	Aug 12, 2026	BUY	Strong Buy +24.5% avg upside 34 analysts	$106.00 38.47% Upside	-9.7%	·
RCKT Rocket Pharmaceuticals	Aug 12, 2026	BUY	Buy +334.7% avg upside 30 analysts	$10.00 159.14% Upside	+13.2%	·
TSHA Taysha Gene Therapies	Aug 11, 2026	BUY	Strong Buy +148.9% avg upside 21 analysts	$17.00 201.33% Upside	-13.6%	·
NTLA Intellia Therapeutics	Aug 06, 2026	BUY	Buy +205.1% avg upside 37 analysts	$49.00 283.96% Upside	+14.5%	·
TNYA Tenaya Therapeutics	Aug 06, 2026	BUY	Strong Buy +1341.2% avg upside 11 analysts	$5.00 614.97% Upside	-5.7%	·
OCGN Ocugen	Aug 06, 2026	BUY	Strong Buy +600.8% avg upside 17 analysts	$11.00 733.40% Upside	+10.5%	·
RYTM Rhythm Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy +18.9% avg upside 21 analysts	$154.00 46.14% Upside	+1.6%	·
BEAM Beam Therapeutics	Aug 05, 2026	BUY	Strong Buy +79.1% avg upside 25 analysts	$78.00 166.26% Upside	+12.6%	·
PVLA Palvella Therapeutics	Aug 05, 2026	BUY	Strong Buy +11.3% avg upside 27 analysts	$232.00 51.74% Upside	-3.2%	·
VRTX Vertex Pharmaceuticals	Aug 04, 2026	HOLD	Strong Buy -18.9% avg upside 62 analysts	$442.00 20.61% Downside	+14.4%	·
PHAR Pharming Group	Aug 03, 2026	BUY	Strong Buy +244.7% avg upside 4 analysts	$38.00 239.26% Upside	+20.0%	·
WVE Wave Life Sciences	May 19, 2026	BUY	Strong Buy +326.9% avg upside 28 analysts	$43.00 781.22% Upside	-16.0%	·
PASG Passage Bio	Apr 21, 2026	BUY	Buy +292.0% avg upside 14 analysts	$23.00 398.96% Upside	-29.9%	·
KRYS Krystal Biotech	Feb 28, 2022	BUY	Strong Buy -27.0% avg upside 20 analysts	$114.00 69.13% Downside	+28.9%	·
SRPT Sarepta Therapeutics	Sep 15, 2021	BUY	Buy +175.1% avg upside 49 analysts	—	+31.7%	·
GILD Gilead Sciences	Jan 04, 2021	BUY	Strong Buy -20.8% avg upside 66 analysts	—	+25.3%	·
INCY Incyte	Jan 04, 2021	BUY	Buy -13.2% avg upside 48 analysts	—	-16.9%	·
QURE uniQure	Jun 25, 2020	HOLD	Strong Buy +24.5% avg upside 29 analysts	—	-37.1%	·
MIRM Mirum Pharmaceuticals	Dec 16, 2019	BUY	Strong Buy +14.9% avg upside 22 analysts	$27.00 72.97% Downside	+3.9%	·
SGMOQ Sangamo Therapeutics	Nov 09, 2018	HOLD	Buy +6506.4% avg upside 16 analysts	$18.00 10426.28% Upside	·	·
EDIT Editas Medicine	Oct 09, 2018	HOLD	Buy +346.1% avg upside 33 analysts	—	-28.3%	·
TECX Tectonic Therapeutic	Oct 09, 2018	BUY	Strong Buy +79.1% avg upside 24 analysts	$35.00 15.25% Upside	-42.0%	·
CRSP Crispr Therapeutics AG	Oct 09, 2018	HOLD	Buy +33.2% avg upside 41 analysts	—	-0.3%	·
KPTI Karyopharm Therapeutics	May 04, 2017	BUY	Strong Buy +900.7% avg upside 18 analysts	$16.00 793.88% Upside	·	·
TCRT Alaunos Therapeutics	Jan 11, 2017	HOLD	Buy +796.3% avg upside 13 analysts	—	·	·
MNKD MannKind	May 13, 2014	HOLD	Buy +75.7% avg upside 22 analysts	—	-44.8%	·

🔒 27 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Whitney Ijem — Frequently Asked Questions

How accurate are Whitney Ijem's stock ratings?

Based on the calls 13Foresight could measure, about 49% of Whitney's ratings were profitable over a one-year hold, with an average return of +1.0% per rating, or -2.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Whitney ranked on 13Foresight?

Whitney Ijem is currently ranked #1848 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Whitney cover?

Whitney most recently has ratings on BMRN, ALNY, ARCT, RARE, NGNE, GUTS, BBIO, RCKT, TSHA, NTLA, TNYA, OCGN and 20 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Whitney Ijem

Rating Distribution

Welcome to 13Foresight!